Response monitoring in multiple myeloma

Meral Beksac, MD, Ankara University, Ankara, Turkey, gives an overview of her talk on response monitoring in multiple myeloma at EBMT 2021. Dr Beksac outlines the most significant prognostic and response monitoring tools, including urine and serum free light chain measurement, next generation sequencing, PET-CT and measurable residual disease (MRD). Dr Beksac also outlines the latest clinical trials employing MRD for myeloma response assessment. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.